过敏性哮喘治疗方法的研究进展
Research Progress in the Treatment Methods of Allergic Asthma
DOI: 10.12677/ACM.2023.1371541, PDF,   
作者: 吾丽凡·吾汗：新疆医科大学儿科学院，新疆 乌鲁木齐；茹 凉#：新疆医科大学第一附属医院儿科中心，新疆 乌鲁木齐
关键词: 过敏性哮喘；传统治疗；变应原治疗；生物制剂；Allergic Asthma； Traditional Treatment； Allergen Therapy； Biological Agents
摘要: 支气管哮喘的发病机制是复杂而多面的，尽管在临床表型上有明显的相似性，但哮喘患者具有多种潜在的显性疾病过程和途径。本文主要讨论过敏性哮喘作为支气管哮喘最常见的表型，总结过敏性哮喘目前的治疗进展，达到未来最佳过敏性哮喘管理所需的靶向治疗方案。
Abstract: The pathogenesis of bronchial asthma is complex and multifaceted. Although there are obvious similarities in clinical phenotypes, patients with asthma have a variety of potential dominant dis-ease processes and pathways. This article mainly discusses allergic asthma as the most common phenotype of bronchial asthma, and summarizes the current progress in the treatment of allergic asthma, so as to achieve the future optimal management of allergic asthma required for targeted therapy.
文章引用：吾丽凡·吾汗, 茹凉. 过敏性哮喘治疗方法的研究进展[J]. 临床医学进展, 2023, 13(7): 11050-11055. https://doi.org/10.12677/ACM.2023.1371541

参考文献

[1] 伊娜, 刘婷婷, 周宇畅, 等. 1990-2019年中国儿童青少年哮喘疾病负担分析[J]. 中华流行病学杂志, 2023, 44(2): 235-242.
[2] (2017) Global, Regional, and National Deaths, Prevalence, Disability-Adjusted Life Years, and Years Lived with Disability for Chronic Obstructive Pulmonary Disease and Asthma, 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015. The Lancet. Respiratory Medicine, 5, 691-706.
[3] 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版) [J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354.
[4] Walter, C.G. (2022) Corrigendum to “Manifesto on Small Airway Involvement and Management in Asthma and Chronic Obstructive Pulmonary Disease: An Interasma (Global Asthma Association—GAA) and World Allergy Organization (WAO) Document Endorsed by Allergic Rhinitis and Its Impact on Asthma (Aria) and Global Al-lergy and Asthma European Network (ga2len)” [World Allergy Organ (2016) 9-37]. The World Allergy Organization Journal, 15, Article ID: 100596. [Google Scholar] [CrossRef] [PubMed]
[5] Akar-Ghibril, N., Casale, T., Custovic, A., et al. (2020) Allergic Endotypes and Phenotypes of Asthma. The Journal of Allergy and Clinical Immu-nology. In Practice, 8, 429-440. [Google Scholar] [CrossRef] [PubMed]
[6] Singh, D., Garcia, G., Maneechotesuwan, K., et al. (2022) New versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Pre-scribing and Dosing Regimens in Asthma Management. Advances in Therapy, 39, 1895-1914. [Google Scholar] [CrossRef] [PubMed]
[7] Hekking, P.W., Wener, R.R., Amelink, M., et al. (2015) The Prevalence of Severe Refractory Asthma. Journal of Allergy and Clinical Immunology, 135, 896-902. [Google Scholar] [CrossRef] [PubMed]
[8] 张萍萍, 杨丽芬, 梁英, 等. 儿童变应原免疫治疗的临床应用进展[J]. 新医学, 2022, 53(2): 87-92.
[9] Abramson, M.J., Puy, R.M. and Weiner, J.M. (2010) Injection Allergen Im-munotherapy for Asthma. The Cochrane Database of Systematic Reviews, No. 8, Cd001186. [Google Scholar] [CrossRef] 
[10] Hanania, N.A., Fortis, S., Haselkorn, T., et al. (2022) Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of Extra. The Journal of Allergy and Clinical Immunology. In Practice, 10, 222-228. [Google Scholar] [CrossRef] [PubMed]
[11] Phipatanakul, W., Mauger, D.T., Guilbert, T.W., et al. (2021) Pre-venting Asthma in High Risk Kids (Park) with Omalizumab: Design, Rationale, Methods, Lessons Learned and Adapta-tion. Contemporary Clinical Trials, 100, Article ID: 106228.
[12] Hammad, H. and Lambrecht, B.N. (2021) The Basic Immunology of Asthma. Cell, 184, 2521-2522. [Google Scholar] [CrossRef] [PubMed]
[13] Farne, H.A., Wilson, A., Milan, S., et al. (2022) Anti-IL-5 Thera-pies for Asthma. Cochrane Database of Systematic Reviews, 7, CD010834. [Google Scholar] [CrossRef] 
[14] Kabata, H., Flamar, A.L., Mahlakõiv, T., et al. (2020) Targeted Deletion of the TSLP Receptor Reveals Cellular Mechanisms That Promote Type 2 Airway Inflammation. Mu-cosal Immunology, 13, 626-636. [Google Scholar] [CrossRef] [PubMed]
[15] Gauvreau, G.M., Sehmi, R., Ambrose, C.S., et al. (2020) Thymic Stromal Lymphopoietin: Its Role and Potential as a Therapeutic Target in Asthma. Expert Opinion on Therapeutic Tar-gets, 24, 777-792. [Google Scholar] [CrossRef] [PubMed]
[16] Paplinska-Goryca, M., Misiukiewicz-Stepien, P., Proboszcz, M., et al. (2020) The Expressions of TSLP, IL-33, and IL-17a in Monocyte Derived Dendritic Cells from Asthma and COPD Patients Are Related to Epithelial-Macrophage Interactions. Cells, 9, Article No. 1944. [Google Scholar] [CrossRef] [PubMed]
[17] Chiu, C.J. and Huang, M.T. (2021) Asthma in the Precision Medicine Era: Biologics and Probiotics. International Journal of Molecular Sciences, 22, Article No. 4528. [Google Scholar] [CrossRef] [PubMed]
[18] Pelaia, C., Pelaia, G., Longhini, F., et al. (2021) Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma. Biomedicines, 9, Article No. 1108. [Google Scholar] [CrossRef] [PubMed]
[19] Corren, J., Chen, S., Callan, L., et al. (2020) The Effect of Te-zepelumab on Hospitalizations and Emergency Department Visits in Patients with Severe Asthma. Annals of Allergy, Asthma & Immunology, 125, 211-214. [Google Scholar] [CrossRef] [PubMed]
[20] Menzies-Gow, A., Colice, G., Griffiths, J.M., et al. (2020) Navi-gator: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Effi-cacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. Respiratory Research, 21, Article No. 266. [Google Scholar] [CrossRef] [PubMed]
[21] Hoy, S.M. (2022) Tezepelumab: First Approval. Drugs, 82, 461-468. [Google Scholar] [CrossRef] [PubMed]

为你推荐